RxDoctor Payments Data

Rachel Bier, MD

Endocrinology, Diabetes & Metabolism · Englewood, NJNPI 1902128325

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (49.6%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. Xeris Pharmaceuticals, Inc. accounts for 98.9% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2023 at $7,397 and has fallen 99.8% since, to $17 in 2025.

$12,529in general payments, 2019–2025

Across 25 payments — averaging $501.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Xeris Pharmaceuticals, Inc.$12K
  • Senseonics, Incorporated$126
  • Amgen$17

What the payments were for

  • Consulting fees$6,21050%
  • Speaking & faculty fees$3,88131%
  • Travel & lodging$2,02816%
  • Food & beverage$4103%

General payments by program year

19
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Xeris Pharmaceuticals, Inc.22$12,386
Senseonics, Incorporated2$126
Amgen1$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,529 in reported general payments places this provider in the 85th percentile of 367 endocrinology, diabetes & metabolism providers in New Jersey.

See all endocrinology, diabetes & metabolism providers in New Jersey

Medicare billing

Part B allowed, 2024
$338,154
Medicare patients
259
Services billed
8,912

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide213$225,555
OzempicSemaglutide103$158,876
JardianceEmpagliflozin96$116,672
Evenity (2 Syringes)Romosozumab-Aqqg34$84,526
ForteoTeriparatide11$72,756
Teriparatide19$54,114
FarxigaDapagliflozin Propanediol42$46,623
TrulicityDulaglutide31$37,494
RybelsusSemaglutide12$25,333
WegovySemaglutide18$23,161
Fiasp FlextouchInsulin Aspart (Niacinamide)25$17,095
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/715$16,453
JanuviaSitagliptin Phosphate23$16,345
SynthroidLevothyroxine Sodium106$13,050
VascepaIcosapent Ethyl20$12,547

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenEvenity (2 Syringes)$17$84,52634 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 367 endocrinology, diabetes & metabolism providers in New Jersey.

Other endocrinology, diabetes & metabolism in Englewood

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →